Finance

Beta
Lists
KRYS:NASDAQ
Krystal Biotech Inc
$340.21
-0.94%
(-3.22) 1D
$340.21
0.00% (0.00)
After hours
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KRYS...
Open
$339.21
High
$346.82
Low
$337.60
Mkt. cap
10.03B
Avg. vol.
308.17K
Volume
1.00
P/E ratio
45.50
52-wk high
$356.50
52-wk low
$130.50
EPS
$7.48
Beta
0.53
Shares outstanding
29.48M
No. of employees
295
Open
$339.21
High
$346.82
Low
$337.60
Mkt. cap
10.03B
Avg. vol.
308.17K
Volume
1.00
P/E ratio
45.50
52-wk high
$356.50
52-wk low
$130.50
EPS
$7.48
Beta
0.53
Shares outstanding
29.48M
No. of employees
295
News stories
From sources across the web
About Krystal Biotech Inc
CEO-
Employees295
Founded2016
HeadquartersPittsburgh, Pennsylvania, United States
SectorBiotechnology
Websitekrystalbio.com
Analyst Ratings
Based on 10 analysts giving stock ratings to KRYS in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for KRYS in the last 3 months.
Highest
Current $340.21
$403.00 (+18.46%)
Average
$340.50 (+0.09%)
Lowest
$284.00 (-16.52%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Ritu Baral
TD Cowen
Buy
Maintained
$403.00
+18.5%
06/18/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$361.00
+6.1%
06/17/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$364.00
+7%
05/31/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
05/18/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$300.00
-11.8%
05/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$284.00
-16.5%
05/04/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$378.00
+11.1%
05/05/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$323.00
-5.1%
05/04/2026
William Maughan
Clear Street
Buy
Maintained
$311.00
-8.6%
05/04/2026
Kalpit Patel
Wolfe Research
Hold
Initiated
-
-
03/26/2026
Roger Song
Jefferies
Buy
Maintained
$371.00
+9.1%
02/17/2026
Andrea Tan
Goldman Sachs
Buy
Reiterated
$327.00
-3.9%
01/30/2026
Last report
May 4, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.83 / $1.42
+28.97%beat
Revenue / Est. (USD)
116.36M / 112.13M
+3.77%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
96.04M
97.80M
107.10M
116.36M
Cost of goods sold
7.16M
4.26M
6.59M
6.32M
Cost of revenue
7.16M
4.26M
6.59M
6.32M
Research and development expenses
14.41M
14.58M
14.79M
15.33M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.16M
37.58M
41.45M
41.01M
Operating expense
49.57M
52.16M
56.24M
56.34M
Total operating expenses
56.74M
56.43M
62.84M
62.67M
Operating income
39.31M
41.37M
44.27M
53.69M
Other non operating income
-
-
-
-
EBT including unusual items
46.78M
47.97M
51.13M
61.44M
EBT excluding unusual items
46.78M
47.97M
51.13M
61.44M
Income tax expense
8.44M
-31.40M
-269.00K
5.51M
Effective tax rate
18.05%
-65.46%
-0.53%
8.97%
Other operating expenses
-
-
-
-
Net income
38.33M
79.36M
51.40M
55.93M
Net profit margin
39.91%
81.15%
47.99%
48.07%
Earnings per share
1.29
2.66
1.70
1.83
Interest and investment income
7.47M
6.59M
6.86M
7.75M
Interest expense
-
-
-
-
Net interest expenses
7.47M
6.59M
6.86M
7.75M
Depreciation and amortization charges
-
-
-
-
EBITDA
39.62M
41.68M
44.83M
54.21M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer